Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lessened its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 63.6% during the 3rd quarter, Holdings Channel reports. The firm owned 100,851 shares of the company’s stock after selling 176,081 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Syndax Pharmaceuticals were worth $1,552,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Phoenix Financial Ltd. acquired a new stake in Syndax Pharmaceuticals during the 2nd quarter worth approximately $701,000. Franklin Resources Inc. increased its position in shares of Syndax Pharmaceuticals by 14.5% during the second quarter. Franklin Resources Inc. now owns 2,359,677 shares of the company’s stock worth $22,098,000 after acquiring an additional 298,272 shares during the period. Aberdeen Group plc raised its stake in shares of Syndax Pharmaceuticals by 129.1% in the second quarter. Aberdeen Group plc now owns 303,426 shares of the company’s stock valued at $2,842,000 after acquiring an additional 170,993 shares in the last quarter. Schroder Investment Management Group boosted its holdings in Syndax Pharmaceuticals by 112.2% in the second quarter. Schroder Investment Management Group now owns 122,163 shares of the company’s stock valued at $1,144,000 after purchasing an additional 64,598 shares during the period. Finally, Aisling Capital Management LP grew its stake in Syndax Pharmaceuticals by 28.5% during the 2nd quarter. Aisling Capital Management LP now owns 1,316,806 shares of the company’s stock worth $12,325,000 after purchasing an additional 291,806 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. BTIG Research reiterated a “buy” rating and set a $56.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, December 9th. JPMorgan Chase & Co. reduced their price objective on shares of Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, November 12th. Finally, UBS Group boosted their target price on shares of Syndax Pharmaceuticals from $35.00 to $38.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.20.

Syndax Pharmaceuticals Trading Down 1.4%

NASDAQ SNDX opened at $20.31 on Friday. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.58 and a 12 month high of $22.73. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -5.63 and a beta of 0.48. The company has a debt-to-equity ratio of 2.78, a current ratio of 4.64 and a quick ratio of 4.42. The firm’s fifty day moving average price is $20.57 and its 200 day moving average price is $16.58.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Monday, November 3rd. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.04. The business had revenue of $45.87 million for the quarter, compared to analysts’ expectations of $49.08 million. Syndax Pharmaceuticals had a negative return on equity of 160.60% and a negative net margin of 279.31%.The business’s revenue was up 266.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.98) earnings per share. On average, sell-side analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.